Do analysts rate VRAX or PPCB?

Virax Biolabs Group currently has a consensus price target of $1.00, suggesting a potential upside of 446.45%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, equities analysts plainly believe Virax Biolabs Group is more favorable than Propanc Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, VRAX or PPCB?

Virax Biolabs Group has higher revenue and earnings than Propanc Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $2.99K 266.10 -$6.06M N/A N/A Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A

Is VRAX or PPCB more profitable?

Virax Biolabs Group's return on equity of 0.00% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Virax Biolabs Group N/A N/A N/A Propanc Biopharma N/A -151.28% -109.53%

Which has stronger valuation and earnings, VRAX or ARTL?

Virax Biolabs Group has higher revenue and earnings than Artelo Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $2.99K 266.10 -$6.06M N/A N/A Artelo Biosciences N/A N/A -$12.88M -$32.74 N/A

Is VRAX or ARTL more profitable?

Virax Biolabs Group's return on equity of 0.00% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Virax Biolabs Group N/A N/A N/A Artelo Biosciences N/A -1,600.12% -224.62%

Do analysts rate VRAX or VIVS?

Virax Biolabs Group currently has a consensus price target of $1.00, suggesting a potential upside of 446.45%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, research analysts plainly believe Virax Biolabs Group is more favorable than VivoSim Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, VRAX or VIVS?

VivoSim Labs has higher revenue and earnings than Virax Biolabs Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $2.99K 266.10 -$6.06M N/A N/A VivoSim Labs $140K 22.09 -$2.48M -$3.15 N/A

Which has higher valuation & earnings, VRAX or SNYR?

Virax Biolabs Group has higher earnings, but lower revenue than Synergy CHC. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $2.99K 266.10 -$6.06M N/A N/A Synergy CHC $30.38M 0.10 -$12.34M -$1.40 N/A

Which has preferable earnings and valuation, VRAX or DCOY?

Virax Biolabs Group has higher revenue and earnings than Decoy Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $2.99K 266.10 -$6.06M N/A N/A Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A

Is VRAX or DCOY more profitable?

Virax Biolabs Group's return on equity of 0.00% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Virax Biolabs Group N/A N/A N/A Decoy Therapeutics N/A -395.42% -193.30%

Virax Biolabs Group (VRAX) Competitors

$0.18 0.00 (-0.54%)

As of 12:16 PM Eastern

Compare

VRAX vs. PPCB, ARTL, VIVS, SNYR, and DCOY

Should you buy Virax Biolabs Group stock or one of its competitors? MarketBeat compares Virax Biolabs Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Virax Biolabs Group include Propanc Biopharma (PPCB), Artelo Biosciences (ARTL), VivoSim Labs (VIVS), Synergy CHC (SNYR), and Decoy Therapeutics (DCOY). These companies are all part of the "pharmaceutical products" industry.

How does Virax Biolabs Group compare to Propanc Biopharma?

Virax Biolabs Group (NASDAQ:VRAX) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Virax Biolabs Group currently has a consensus price target of $1.00, suggesting a potential upside of 446.45%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, equities analysts plainly believe Virax Biolabs Group is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Propanc Biopharma had 5 more articles in the media than Virax Biolabs Group. MarketBeat recorded 7 mentions for Propanc Biopharma and 2 mentions for Virax Biolabs Group. Propanc Biopharma's average media sentiment score of 0.80 beat Virax Biolabs Group's score of 0.43 indicating that Propanc Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Virax Biolabs Group	Neutral
Propanc Biopharma	Positive

Virax Biolabs Group's return on equity of 0.00% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Propanc Biopharma	N/A	-151.28%	-109.53%

Virax Biolabs Group has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.48, indicating that its stock price is 248% more volatile than the broader market.

Virax Biolabs Group has higher revenue and earnings than Propanc Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$2.99K	266.10	-$6.06M	N/A	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

8.6% of Virax Biolabs Group shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by insiders. Comparatively, 28.5% of Propanc Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Virax Biolabs Group beats Propanc Biopharma on 9 of the 12 factors compared between the two stocks.

How does Virax Biolabs Group compare to Artelo Biosciences?

Virax Biolabs Group (NASDAQ:VRAX) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Virax Biolabs Group has higher revenue and earnings than Artelo Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$2.99K	266.10	-$6.06M	N/A	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A

Virax Biolabs Group has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.13, indicating that its share price is 113% less volatile than the broader market.

Virax Biolabs Group presently has a consensus target price of $1.00, suggesting a potential upside of 446.45%. Artelo Biosciences has a consensus target price of $54.00, suggesting a potential upside of 3,938.89%. Given Artelo Biosciences' higher probable upside, analysts clearly believe Artelo Biosciences is more favorable than Virax Biolabs Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by insiders. Comparatively, 3.2% of Artelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Artelo Biosciences had 2 more articles in the media than Virax Biolabs Group. MarketBeat recorded 4 mentions for Artelo Biosciences and 2 mentions for Virax Biolabs Group. Artelo Biosciences' average media sentiment score of 0.72 beat Virax Biolabs Group's score of 0.43 indicating that Artelo Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Virax Biolabs Group	Neutral
Artelo Biosciences	Positive

Virax Biolabs Group's return on equity of 0.00% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Artelo Biosciences	N/A	-1,600.12%	-224.62%

Summary

Virax Biolabs Group beats Artelo Biosciences on 9 of the 12 factors compared between the two stocks.

How does Virax Biolabs Group compare to VivoSim Labs?

Virax Biolabs Group (NASDAQ:VRAX) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Virax Biolabs Group has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by company insiders. Comparatively, 2.5% of VivoSim Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Virax Biolabs Group and Virax Biolabs Group both had 2 articles in the media. VivoSim Labs' average media sentiment score of 1.28 beat Virax Biolabs Group's score of 0.43 indicating that VivoSim Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
Virax Biolabs Group	Neutral
VivoSim Labs	Positive

Virax Biolabs Group has a net margin of 0.00% compared to VivoSim Labs' net margin of -861.27%. Virax Biolabs Group's return on equity of 0.00% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
VivoSim Labs	-861.27%	-15.51%	-11.31%

Virax Biolabs Group currently has a consensus price target of $1.00, suggesting a potential upside of 446.45%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, research analysts plainly believe Virax Biolabs Group is more favorable than VivoSim Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

VivoSim Labs has higher revenue and earnings than Virax Biolabs Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$2.99K	266.10	-$6.06M	N/A	N/A
VivoSim Labs	$140K	22.09	-$2.48M	-$3.15	N/A

Summary

Virax Biolabs Group beats VivoSim Labs on 9 of the 13 factors compared between the two stocks.

How does Virax Biolabs Group compare to Synergy CHC?

Virax Biolabs Group (NASDAQ:VRAX) and Synergy CHC (NASDAQ:SNYR) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Virax Biolabs Group has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Virax Biolabs Group's return on equity of 0.00% beat Synergy CHC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Synergy CHC	-60.02%	-19.51%	-30.30%

Virax Biolabs Group currently has a consensus target price of $1.00, indicating a potential upside of 446.45%. Synergy CHC has a consensus target price of $6.25, indicating a potential upside of 2,969.74%. Given Synergy CHC's stronger consensus rating and higher possible upside, analysts plainly believe Synergy CHC is more favorable than Virax Biolabs Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Synergy CHC	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Virax Biolabs Group has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Synergy CHC has a beta of -0.27, indicating that its stock price is 127% less volatile than the broader market.

In the previous week, Synergy CHC had 10 more articles in the media than Virax Biolabs Group. MarketBeat recorded 12 mentions for Synergy CHC and 2 mentions for Virax Biolabs Group. Virax Biolabs Group's average media sentiment score of 0.43 beat Synergy CHC's score of -0.47 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company	Overall Sentiment
Virax Biolabs Group	Neutral
Synergy CHC	Neutral

Virax Biolabs Group has higher earnings, but lower revenue than Synergy CHC.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$2.99K	266.10	-$6.06M	N/A	N/A
Synergy CHC	$30.38M	0.10	-$12.34M	-$1.40	N/A

8.6% of Virax Biolabs Group shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by insiders. Comparatively, 32.9% of Synergy CHC shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Virax Biolabs Group beats Synergy CHC on 9 of the 14 factors compared between the two stocks.

How does Virax Biolabs Group compare to Decoy Therapeutics?

Virax Biolabs Group (NASDAQ:VRAX) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Virax Biolabs Group has higher revenue and earnings than Decoy Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$2.99K	266.10	-$6.06M	N/A	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

In the previous week, Decoy Therapeutics had 2 more articles in the media than Virax Biolabs Group. MarketBeat recorded 4 mentions for Decoy Therapeutics and 2 mentions for Virax Biolabs Group. Virax Biolabs Group's average media sentiment score of 0.43 beat Decoy Therapeutics' score of 0.37 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company	Overall Sentiment
Virax Biolabs Group	Neutral
Decoy Therapeutics	Neutral

Virax Biolabs Group has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

Virax Biolabs Group currently has a consensus target price of $1.00, suggesting a potential upside of 446.45%. Decoy Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 387.80%. Given Virax Biolabs Group's higher possible upside, analysts clearly believe Virax Biolabs Group is more favorable than Decoy Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Virax Biolabs Group's return on equity of 0.00% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Decoy Therapeutics	N/A	-395.42%	-193.30%

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by insiders. Comparatively, 1.7% of Decoy Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Virax Biolabs Group beats Decoy Therapeutics on 8 of the 10 factors compared between the two stocks.

Get Virax Biolabs Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRAX vs. The Competition

Export

Metric	Virax Biolabs Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$795K	$3.40B	$6.50B	$12.32B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	N/A	20.12	24.00	24.65
Price / Sales	266.10	326.92	543.88	171.03
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.15	8.09	10.73	6.84
Net Income	-$6.06M	$23.89M	$3.56B	$337.45M
7 Day Performance	-12.36%	3.15%	1.34%	2.48%
1 Month Performance	19.22%	1.14%	2.25%	4.36%
1 Year Performance	-79.26%	46.12%	26.20%	32.45%

Virax Biolabs Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRAX Virax Biolabs Group	2.7537 of 5 stars	$0.18 -0.5%	$1.00 +446.4%	-79.2%	$795K	$2.99K	N/A	5	Short Interest Increase
PPCB Propanc Biopharma	1.1822 of 5 stars	$1.35 -2.2%	N/A	-98.9%	$3.14M	N/A	N/A	1	News Coverage Buyback Announcement
ARTL Artelo Biosciences	1.6604 of 5 stars	$1.30 -2.3%	$54.00 +4,053.8%	-93.7%	$3.10M	N/A	N/A	5	Gap Down
VIVS VivoSim Labs	1.43 of 5 stars	$1.18 -0.8%	N/A	-29.2%	$3.10M	$140K	N/A	20	Positive News
SNYR Synergy CHC	2.1413 of 5 stars	$0.19 -4.9%	$6.25 +3,242.2%	-90.6%	$2.97M	$30.38M	N/A	40	News Coverage Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRAX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Virax Biolabs Group (VRAX) Competitors

VRAX vs. PPCB, ARTL, VIVS, SNYR, and DCOY

How does Virax Biolabs Group compare to Propanc Biopharma?

Summary

How does Virax Biolabs Group compare to Artelo Biosciences?

Summary

How does Virax Biolabs Group compare to VivoSim Labs?

Summary

How does Virax Biolabs Group compare to Synergy CHC?

Summary

How does Virax Biolabs Group compare to Decoy Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX vs. The Competition

Virax Biolabs Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Virax Biolabs Group (VRAX) Competitors

VRAX vs. PPCB, ARTL, VIVS, SNYR, and DCOY

How does Virax Biolabs Group compare to Propanc Biopharma?

Do analysts rate VRAX or PPCB?

Does the media favor VRAX or PPCB?

Is VRAX or PPCB more profitable?

Which has more risk & volatility, VRAX or PPCB?

Which has higher earnings and valuation, VRAX or PPCB?

Do institutionals and insiders believe in VRAX or PPCB?

Summary

How does Virax Biolabs Group compare to Artelo Biosciences?

Which has stronger valuation and earnings, VRAX or ARTL?

Which has more risk and volatility, VRAX or ARTL?

Do analysts rate VRAX or ARTL?

Do insiders and institutionals believe in VRAX or ARTL?

Does the media refer more to VRAX or ARTL?

Is VRAX or ARTL more profitable?

Summary

How does Virax Biolabs Group compare to VivoSim Labs?

Which has more volatility and risk, VRAX or VIVS?

Do insiders & institutionals believe in VRAX or VIVS?

Does the media refer more to VRAX or VIVS?

Is VRAX or VIVS more profitable?

Do analysts rate VRAX or VIVS?

Which has better earnings & valuation, VRAX or VIVS?

Summary

How does Virax Biolabs Group compare to Synergy CHC?

Is VRAX or SNYR more profitable?

Do analysts rate VRAX or SNYR?

Which has more risk & volatility, VRAX or SNYR?

Does the media refer more to VRAX or SNYR?

Which has higher valuation & earnings, VRAX or SNYR?

Do insiders and institutionals believe in VRAX or SNYR?

Summary

How does Virax Biolabs Group compare to Decoy Therapeutics?

Which has preferable earnings and valuation, VRAX or DCOY?

Does the media favor VRAX or DCOY?

Which has more volatility and risk, VRAX or DCOY?

Do analysts prefer VRAX or DCOY?

Is VRAX or DCOY more profitable?

Do institutionals & insiders have more ownership in VRAX or DCOY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX vs. The Competition

Virax Biolabs Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools